公开(公告)号：EP0598816B1

公开(公告)日：1999-06-23

申请号：EP92917879.6

申请日：1992-08-11

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A. ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

发明人： LOBET, Yves ,  SIMON, Markus ,  SCHAIBLE, Ulrich ,  WALLICH, Reinhard Deutsches Krebsforschungszentrum ,  KRAMER, Michael

IPC分类号： C12N15/31 ,  C12N15/62 ,  A61K39/02

CPC分类号： C07K16/1207 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C07K14/20 ,  C07K2319/40 ,  C12N2760/16022 ,  C12Q1/689 ,  C12R1/01 ,  Y02A50/401 ,  Y02A50/57 ,  Y10S530/806 ,  Y10S530/82 ,  Y10S530/825

摘要： The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

公开(公告)号：EP0614465B1

公开(公告)日：1999-03-17

申请号：EP92923486.2

申请日：1992-11-11

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： DE WILDE, Michel ,  COHEN, Joseph SmithKline Beecham Biologicals s.a.

IPC分类号： C07K14/445 ,  C12N15/62 ,  A61K39/015 ,  C12N7/04

CPC分类号： C07K14/445 ,  A61K39/00 ,  C07K14/005 ,  C07K2319/40 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123 ,  Y02A50/412

摘要： A novel hybrid protein is provided which comprises a portion of the CS protein of P. falciparum and the surface antigen of Hepatitis B virus. The use of this protein for vaccination purposes is disclosed.

公开(公告)号：EP0874051A2

公开(公告)日：1998-10-28

申请号：EP98201598.4

申请日：1992-08-11

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A. ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

发明人： Lobet, Yves, SmithKline Beecham Biologicals s.a. ,  Simon, Markus ,  Schaible, Ulrich ,  Kramer, Michael ,  Wallich, Reinhard, D. K. S. des öffentlichen Rec.

IPC分类号： C12N15/32 ,  C12N15/44 ,  C12N15/62 ,  C07K14/20 ,  C07K14/11 ,  C12R1/01 ,  A61K39/02 ,  C12N1/20

CPC分类号： C07K16/1207 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C07K14/20 ,  C07K2319/40 ,  C12N2760/16022 ,  C12Q1/689 ,  C12R1/01 ,  Y02A50/401 ,  Y02A50/57 ,  Y10S530/806 ,  Y10S530/82 ,  Y10S530/825

摘要： The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

摘要翻译： 本发明涉及新颖的疏螺旋体和由其衍生的OspA抗原。 这些抗原与已知的OspA几乎没有同源性，因此可用作疫苗和诊断试剂。 还公开了基于来自不同Borrelia组的OspA的多组分疫苗。

公开(公告)号：EP0835663A2

公开(公告)日：1998-04-15

申请号：EP97204034.9

申请日：1993-05-15

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： Petre, Jean, SmithKline Beecham Biologicals S.A ,  Hauser, Pierre, SmithKline Beecham Biologicals s.a

IPC分类号： A61K39/295 ,  A61K39/39

CPC分类号： A61K39/292 ,  A61K39/0017 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32434 ,  Y02A50/464 ,  Y02A50/466

摘要： Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37° C and is highly immunogenic, for example when the vaccine is administered to infants. The compositions typically comprise HBsAg adsorbed to aluminium phosphate and other antigens, especially those suitable for use in a paediatric vaccine, adsorbed to aluminium phosphate or aluminium hydroxide. Methods for preparing the vaccines and the use of aluminium phosphate to stabilise HBsAg in a multivalent vaccine formulation are also described.

摘要翻译： 描述包含乙型肝炎表面抗原（HBsAg）的稳定和有效的多价疫苗组合物，其中HBsAg组分在37℃下稳定一周，并且是高度免疫原性的，例如当将疫苗施用于婴儿时。 组合物通常包含吸附到磷酸铝上的HBsAg，以及吸附在磷酸铝或氢氧化铝上的适用于小儿疫苗的其它抗原。 还描述了制备疫苗的方法和使用磷酸铝来稳定多价疫苗制剂中的HBsAg。

公开(公告)号：EP0824360A1

公开(公告)日：1998-02-25

申请号：EP96911776.0

申请日：1996-04-16

申请人： HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE ,  SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： SNAPPER, Clifford M. ,  MOND, James J. ,  CAPIAU, Carine ,  HAUSER, Pierre ,  PRIEELS, Jean-Paul

IPC分类号： A61K39 ,  A61P37 ,  C07K14

CPC分类号： C07K14/285 ,  A61K39/385 ,  A61K2039/55516 ,  A61K2039/55594 ,  A61K2039/6068 ,  Y02A50/482

摘要： The present invention provides a method of inducing or enhancing an immune response to polysaccharides or other T cell-independent antigen by the coadministration of the antigen with bacterial lipoproteins (including covalent attachment of the antigen and lipoproteins). In a preferred embodiment, the lipoprotein of the invention is lipoprotein D.

公开(公告)号：EP0822831A1

公开(公告)日：1998-02-11

申请号：EP96910019.0

申请日：1996-04-01

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： GARCON, Nathalie, Marie-Josephe, Claude ,  FRIEDE, Martin

IPC分类号： A61K39 ,  A61P31 ,  A61P35 ,  A61P37

CPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/245 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  C12N2710/16634 ,  C12N2730/10134 ,  Y02A50/412 ,  Y02A50/464

摘要： The invention relates to a vaccine composition comprising a antigen, an immunologically active saponin fraction and a sterol.

公开(公告)号：EP0735898A1

公开(公告)日：1996-10-09

申请号：EP95904511.0

申请日：1994-12-20

申请人： SMITHKLINE BEECHAM BIOLOGICALS s.a.

发明人： MOMIN, P.M., SmithKline Beecham Bio.(S.A.) ,  GARCON, N. Marie-J., SmithKline Beecham Bio.(S.A.)

IPC分类号： A61K ,  A61K9 ,  A61K39 ,  A61K47 ,  A61P37

CPC分类号： A61K39/39 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  Y02A50/412

摘要： The present invention provides vaccine compositions comprising an oil in water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.

公开(公告)号：EP0687271A1

公开(公告)日：1995-12-20

申请号：EP94909902.0

申请日：1994-02-28

申请人： SMITHKLINE BEECHAM BIOLOGICALS s.a.

发明人： CAPIAU, Carine, SmithKline Beecham Biologicals ,  COMBERBACH, Martin, SmithKline Beecham Biologicals ,  ROELANTS, Piet, SmithKline Beecham Biologicals ,  PETRE, Jean, SmithKline Beecham Biologicals (S.A.)

IPC分类号： C12P21 ,  A61K39 ,  A61P31 ,  C07K1 ,  C07K14 ,  C12N1 ,  C12R1

CPC分类号： C07K14/235 ,  A61K39/00 ,  C12N1/02 ,  Y10S530/82 ,  Y10S530/825

摘要： Process for extracting a cell-bound protein of bacterial origin comprising contacting a suspension of the cell-bound protein with a flocculating agent prior to heat treatment.

公开(公告)号：EP0675741A1

公开(公告)日：1995-10-11

申请号：EP94904178.0

申请日：1993-12-21

申请人： SMITHKLINE BEECHAM BIOLOGICALS s.a.

发明人： THILLY, Jacques

IPC分类号： A61M5 ,  B01L9

CPC分类号： B01L9/543 ,  A61M5/008 ,  A61M2207/00

摘要： For storage of syringes, a support rack comprising a plurality of elongate fingers (2) connected together at one end by a spine member (1) is used. The fingers (2) define parallel support channels (5) open at one end, and the syringes are stored in the channels (5) with their lips or wings (4) resting on the elongate fingers (2). Also disclosed are support cradles, storage boxes, and lifting devices for handling the loaded racks. The support rack is better adapted than existing systems for cooperation with automated machinery since it can receive syringes into the channels by a horizontal translation movement, readily provided by a simple pushing device.

公开(公告)号：EP0666751A1

公开(公告)日：1995-08-16

申请号：EP93921524.0

申请日：1993-09-17

申请人： SMITHKLINE BEECHAM BIOLOGICALS s.a. ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA c/o as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVI

发明人： FUNKHOUSER, Ann, W. ,  EMERSON, Suzanne, U. ,  PURCELL, Robert, H. ,  D'HONDT, Eric

IPC分类号： C12N15 ,  A61K35 ,  A61K39 ,  A61P31 ,  C07K14 ,  C12N7 ,  C12P21 ,  C12R1

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  C12N7/00 ,  C12N2770/32421 ,  C12N2770/32422 ,  C12N2770/32432 ,  C12N2770/32434 ,  Y02A50/464

摘要： A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.